Landscapes / Targets
APOC3
3 drugs act on APOC3, in 9 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs3
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
APOC-III-directed RNA Interaction; antisense oligonucleotide |
Approved | Mar 2027Phase 3 trial completes | |||
| How it works | A short strand of genetic material that blocks one gene's message | ||||
| Next date | Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia | ||||
| Open drug page | |||||
Small interfering RNA |
Arrowhead · Public ARWR |
Approved | Jul 2028Phase 3 trial completes | ||
| How it works | A short strand of RNA that switches off one gene | ||||
| Next date | Jul 2028 · Phase 3 trial completes | ||||
| Also tested for | Hypertriglyceridemia, Severe Hypertriglyceridemia | ||||
| Open drug page | |||||
— |
Hengrui · Public 600276.SS |
Phase 2 | Jun 2027Phase 2 trial completes | ||
| Next date | Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Hyperlipidemia, Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 3 of 3 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026